Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyMVectin in Healthy Adults
NCT02594566Phase 1Withdrawn
- Sponsor
- Virginia Commonwealth University
- Start
- Nov 2015
- Primary completion
- Aug 2016
- Modality
- Prophylactic Vaccines, Lipid-based Nanoparticles, DNA Vaccines
01
Overview
Phase 1, open-label, single-arm trial of CyMVectin in cytomegalovirus infection (CMV), sponsored by Virginia Commonwealth University. Primary endpoints: Number of participants with treatment-related adverse events at Day 182 and Number of participants with treatment-related adverse events of special interest at Day 420. Planned start Nov 2015; status: withdrawn.
02
Drugs
CyMVectin
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT02594566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02594566.